BOOK
Management of Gastric Cancer, An Issue of Surgical Oncology Clinics - E-Book
(2012)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, Guest Edited by Neal Wilkinson, MD, is devoted to the Management of Gastric Cancer. Articles in this issue will focus on Epidemiology; Genetics and Prophylactic Surgery; Endoscopic Diagnosis & Staging; Gastric Stromal Tumors (GIST); Management of Early Stage Gastric Cancer; Endoscopic Mucosal Resection (EMR); Tailored Lymphadenectomy; Laparoscopic Resection Gastric Cancer - Western Experience; Gastric Cancer - Eastern Experience; Update of Gastric Cancer Clinical Trials; Preoperative and Postoperative Chemotherapy for Gastric Cancer; and Phase I and II Clinical Trials.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | Cover | ||
| Management of\rGastric Cancer | i | ||
| Copyright Page\r | ii | ||
| Contributors | iii | ||
| Table of\r Contents | vii | ||
| Foreword | xiii | ||
| Preface | xv | ||
| Chapter 1. Gastric Cancer:Endoscopic Diagnosisand Staging | 1 | ||
| KEYWORDS | 1 | ||
| CLASSIFICATION AND STAGING | 1 | ||
| ENDOSCOPIC DETECTION | 3 | ||
| ENDOSCOPIC IMAGE–ENHANCING TECHNOLOGIES | 6 | ||
| ENDOSCOPIC ULTRASOUND | 9 | ||
| T STAGE | 9 | ||
| N STAGE | 10 | ||
| COMPARISON WITH OTHER IMAGING MODALITIES | 10 | ||
| METASTATIC DISEASE | 10 | ||
| EUS FOR EGC | 11 | ||
| LINITIS PLASTICA | 12 | ||
| SCREENING | 13 | ||
| SUMMARY | 14 | ||
| ACKNOWLEDGMENTS | 14 | ||
| REFERENCES | 14 | ||
| Chapter 2. Gastrointestinal Stromal Tumorsof the Stomach | 21 | ||
| KEYWORDS | 21 | ||
| PREOPERATIVE IMAGING | 22 | ||
| STAGING | 22 | ||
| PATHOLOGY | 23 | ||
| MOLECULAR ANALYSIS | 23 | ||
| TECHNIQUES OF LAPAROSCOPIC AND OPEN RESECTION | 24 | ||
| ADJUVANT TARGETED THERAPY | 25 | ||
| NEOADJUVANT TARGETED THERAPY | 27 | ||
| RESISTANCE TO TARGETED THERAPY | 28 | ||
| SUMMARY | 29 | ||
| REFERENCES | 30 | ||
| Chapter 3. Familial GastricCancer: Genetics,Diagnosis, and Management | 35 | ||
| KEYWORDS | 35 | ||
| CONSENSUS GUIDELINES | 36 | ||
| FAMILIAL GASTRIC CANCER: EPIDEMIOLOGY, RISK ASSESSMENT, AND PENETRANCE | 37 | ||
| GENETICS OF HDGC | 37 | ||
| PATHOLOGY OF HDGC | 42 | ||
| MODELS OF HDGC | 43 | ||
| CDH1 GENETIC TESTING AND MUTATION SEARCHING | 45 | ||
| MINIMUM AGE FOR GENETIC TESTING AND INTERVENTIONS IN HDGC | 46 | ||
| SURVEILLANCE AND SCREENING GASTROSCOPY IN HDGC | 47 | ||
| TOTAL GASTRECTOMY IN HDGC | 48 | ||
| SUMMARY | 51 | ||
| ACKNOWLEDGMENTS | 52 | ||
| REFERENCES | 52 | ||
| Chapter 4. Standard D2 and Modified Nodal Dissection for Gastric Adenocarcinoma | 57 | ||
| DEFINITION OF THE NODAL STATIONS AND THE D1 AND D2 NODAL DISSECTIONS | 58 | ||
| THE TECHNIQUE OF D2 NODAL DISSECTION (DISTAL AND TOTAL GASTRECTOMY) | 60 | ||
| INDICATION FOR MODIFICATIONS OF THE D2 NODAL DISSECTION | 64 | ||
| MARUYAMA INDEX AND THE D2 NODAL DISSECTION | 66 | ||
| LEARNING CURVE OF THE D2 NODAL DISSECTION AND SURGICAL QUALITY CONTROL | 67 | ||
| FUTURE DIRECTION OF GASTRIC CANCER SURGERY | 69 | ||
| REFERENCES | 69 | ||
| Chapter 5. Gastric Cancer Eastern Experience | 71 | ||
| GUIDELINES FOR THE STANDARD TREATMENT OF GASTRIC CANCER | 71 | ||
| STAGE-SPECIFIC RESULTS OF RESECTED GASTRIC CANCER IN THE WEST AND EAST | 71 | ||
| OVERALL SURVIVAL IN VARIOUS CLINICAL TRIALS IN THE WEST AND EAST | 72 | ||
| STAGE MIGRATION: FACT AND SOURCE OF MIGRATION | 73 | ||
| SPLENECTOMY | 73 | ||
| IMPACT OF D2 DISSECTION ON THE RESULTS OF ADJUVANT TREATMENT | 75 | ||
| SUMMARY | 76 | ||
| REFERENCES | 76 | ||
| Chapter 6. Surgery for Gastric Cancer: What the Trials Indicate | 79 | ||
| EAST-WEST DIFFERENCES IN DIAGNOSIS AND STAGING | 79 | ||
| EXTENT OF ORGAN RESECTION. PROSPECTIVE RANDOMIZED TRAILS ADDRESSING ROUTINE TOTAL GASTRECTOMY VERSUS SUBTOTAL GASTRECTOMY | 80 | ||
| IN SITU AND T-1 DISEASE: ROLE OF ENDOSCOPIC MUCOSAL/SUBMUCOSAL RESECTION | 83 | ||
| EXTENT OF LYMPHADENECTOMY: D1 VERSUS D2 | 84 | ||
| MI AND PLANNING A LOW-MI OPERATION | 88 | ||
| EXTENDED PARA-AORTIC NODE DISSECTION (PRE-1997 D4 LYMPHADENECTOMY) | 91 | ||
| FUTURE TRIALS | 92 | ||
| SUMMARY | 93 | ||
| REFERENCES | 94 | ||
| Chapter 7. Preoperative and Postoperative Chemotherapy for Gastric Cancer | 99 | ||
| RATIONALE FOR CHEMOTHERAPEUTIC STRATEGIES IN GASTRIC CANCER | 100 | ||
| TREATMENT PLANNING AND SURGERY | 100 | ||
| ADJUVANT STRATEGIES | 100 | ||
| NEOADJUVANT STRATEGIES | 105 | ||
| SELECTION OF TREATMENT STRATEGY FOR PATIENTS WITH GASTRIC CANCER | 106 | ||
| ONGOING TRIALS | 107 | ||
| SUMMARY | 108 | ||
| ACKNOWLEDGMENTS | 109 | ||
| REFERENCES | 109 | ||
| Chapter 8. Phase I and I I Clinical Trials for Gastric Cancer | 113 | ||
| CHEMOTHERAPY IN ADVANCED GASTRIC CANCER | 114 | ||
| INHIBITORS OF ANGIOGENESIS | 115 | ||
| STRATEGIES TARGETING THE EGFR | 118 | ||
| MAMMALIAN TARGET OF RAPAMYCIN AND ITS INHIBITION | 121 | ||
| OTHER NOVEL APPROACHES TO THERAPY IN GASTRIC CANCER | 121 | ||
| SUMMARY | 122 | ||
| REFERENCES | 122 | ||
| Chapter 9. Endoscopic Mucosal Resection, Endoscopic Submucosal Dissection,and Beyond: Full-Layer Resection for Gastric Cancer with Nonexposure Technique (CLEAN-NET) | 129 | ||
| BASIC PRINCIPLES OF EMR/ESD | 130 | ||
| BRIEF HISTORY OF THE DEVELOPMENT OF EMR/ESD | 130 | ||
| FULL-LAYER RESECTION | 134 | ||
| CLEAN-NET | 135 | ||
| SUMMARY | 139 | ||
| REFERENCES | 139 | ||
| Chapter 10. Laparoscopic Resection for Gastric Carcinoma: Western Experience | 141 | ||
| LAPAROSCOPIC APPROACHES FOR GASTRIC CARCINOMA: WESTERN EXPERIENCE | 141 | ||
| ACKNOWLEDGMENTS | 154 | ||
| REFERENCES | 154 | ||
| Chapter 11. POSTSCRIPT | 159 | ||
| Chapter 12. Molecular Markersfor Incidence, Prognosis, and Response to Therapy | 161 | ||
| INDIVIDUAL GENETIC ALTERATIONSp53 | 162 | ||
| TYROSINE KINASES AND TARGETED THERAPIES | 165 | ||
| PROTEOMICS | 167 | ||
| MICRORNAs | 167 | ||
| PERSONALIZED LUNG CANCER TREATMENT—CURRENT TRIALS | 168 | ||
| SUMMARY | 169 | ||
| REFERENCES | 169 | ||
| Index | 177 |